From the article:
> Curiously, this experimental antibiotic had no effect on other species of bacteria, and works only on A. baumannii.
This is an oversimplified claim made by the BBC article, but broadly aligns with the research paper claim that the identified drug is specifically not broad-spectrum and not active against e.g. Pseudomonal and Staphylococcal species. The identified drug candidate is unlikely to ever see broad use because of the low activity against many clinically relevant bacteria.
The most common use case for this candidate, should it see approval through the FDA process for this indication, will be for treatment of hospitalized patients who, while waiting for culture results, have failed broad-spectrum regimes and whose culture results demonstrate Acinetobacter infections.
That's not to say that regulating its use isn't a good idea, just that it's really complicated.
This is currently the situation in India, where the bulk of our antibiotics are manufactured.